a year ago
SMMT
AnalystsBradley CaninoBradley Canino's Stock Forecasts
AnalystsBradley Canino
Sectors:
Analyst Ranking
Bottom 12%
#4430 out of 4986 analysts
Average Return
-1.74%
Win Rate
31%27 out of 88
Risk vs Reward
Poor
Good
Bradley Canino's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Summit Therapeutics IncSMMT | +441.18% | $3.74 | $20.24 | 2024-03-25 - 2025-03-25 | Strong Buy |
Celcuity IncCELC | +229.04% | $15.77 | $51.89 | 2024-08-14 - 2025-08-14 | Strong Buy |
Celcuity IncCELC | +222.33% | $15.27 | $49.22 | 2024-10-06 - 2025-08-19 | Strong Buy |
Merus NvMRUS | +147.91% | $21.10 | $52.31 | 2023-10-23 - 2024-10-23 | Strong Buy |
Nuvalent IncNUVL | +121.46% | $45.63 | $101.05 | 2023-09-26 - 2024-09-26 | Strong Buy |
Bradley Canino Analyst Color
Get additional color on Bradley Canino's coverage of popular stocks
a year ago
NUVL
a year ago
SMMT
a year ago
MRUS
2 years ago
CCCC
Bradley Canino's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Black Diamond Therapeutics IncBDTX | 5 | Strong Buy | $15.00 | +466.04% | Maintains | 5 months ago |
Alx Oncology Holdings IncALXO | 7 | Hold | $1.50 | +68.54% | Maintains | 5 months ago |
Cullinan Therapeutics IncCGEM | 2 | Strong Buy | $19.00 | +150.66% | Maintains | 6 months ago |
Relay Therapeutics IncRLAY | 5 | Strong Buy | $23.00 | +576.47% | Maintains | 6 months ago |
Arvinas IncARVN | 6 | Strong Buy | $51.00 | +614.29% | Maintains | 6 months ago |
Janux Therapeutics IncJANX | 2 | Strong Buy | $115.00 | +365.59% | Maintains | 9 months ago |
Affimed NvAFMDQ | 6 | Hold | $4.00 | +2,109.94% | Maintains | 9 months ago |
Syndax Pharmaceuticals IncSNDX | 5 | Strong Buy | $41.00 | +166.32% | Maintains | 10 months ago |
Kura Oncology IncKURA | 6 | Hold | $19.00 | +164.26% | Downgrades | 10 months ago |
Celcuity IncCELC | 4 | Strong Buy | $42.00 | -14.67% | Maintains | 10 months ago |
Summit Therapeutics IncSMMT | 4 | Strong Buy | $40.00 | +57.79% | Maintains | a year ago |
Nuvalent IncNUVL | 3 | Strong Buy | $135.00 | +80.80% | Maintains | a year ago |
Oric Pharmaceuticals IncORIC | 1 | Strong Buy | $20.00 | +108.33% | Initiates Coverage On | a year ago |
Pyxis Oncology IncPYXS | 1 | Strong Buy | $10.00 | N/A | Initiates Coverage On | a year ago |
Zentalis Pharmaceuticals IncZNTL | 17 | Strong Buy | $10.00 | N/A | Maintains | a year ago |
Merus NvMRUS | 7 | Strong Buy | $99.00 | N/A | Maintains | a year ago |
C4 Therapeutics IncCCCC | 4 | Strong Buy | $14.00 | N/A | Maintains | a year ago |
Blueprint Medicines CorpBPMC | 6 | Strong Buy | $130.00 | N/A | Maintains | a year ago |
Kymera Therapeutics IncKYMR | 4 | Strong Buy | $55.00 | N/A | Maintains | a year ago |
Deciphera Pharmaceuticals IncDCPH | 6 | Strong Buy | $23.00 | N/A | Maintains | 2 years ago |
Theseus Pharmaceuticals IncTHRX | 1 | Strong Buy | $24.00 | N/A | Initiates Coverage On | 2 years ago |
Turning Point Therapeutics IncTPTX | 2 | Hold | $45.00 | N/A | Maintains | 3 years ago |
Mersana Therapeutics IncMRSN | 1 | Hold | $450.00 | N/A | Initiates Coverage On | 4 years ago |
Seagen IncSGEN | 1 | Hold | $145.00 | N/A | Initiates Coverage On | 4 years ago |
Zymeworks IncZYME | 1 | Buy | $55.00 | N/A | Initiates Coverage On | 4 years ago |
Epizyme IncEPZM | 1 | Buy | $13.00 | N/A | Initiates Coverage On | 4 years ago |
Exelixis IncEXEL | 1 | Buy | $30.00 | N/A | Initiates Coverage On | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.